1887
Rapid communication Open Access
Like 0

Abstract

In January 2019, two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA), which confers reduced susceptibility to baloxavir, were detected from epidemiologically unrelated hospitalised children in Japan. The viruses exhibited reduced susceptibility to baloxavir but were susceptible to neuraminidase inhibitors. Only one of the two children had been treated with baloxavir. An epidemiological analysis suggests possible transmission of the PA I38T mutant A(H3N2) virus among humans.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.12.1900170
2019-03-21
2019-06-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.12.1900170
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/12/eurosurv-24-12-3.html?itemId=/content/10.2807/1560-7917.ES.2019.24.12.1900170&mimeType=html&fmt=ahah

References

  1. Takashita E, Kawakami C, Morita H, Ogawa R, Fujisaki S, Shirakura M, et al. On Behalf Of The Influenza Virus Surveillance Group Of Japan. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018. Euro Surveill. 2019;24(3).  https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800698  PMID: 30670142 
  2. Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018;8(1):9633.  https://doi.org/10.1038/s41598-018-27890-4  PMID: 29941893 
  3. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, et al. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2018;9(3026):3026.  https://doi.org/10.3389/fmicb.2018.03026  PMID: 30574137 
  4. Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, et al. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons. Euro Surveill. 2019;24(3).  https://doi.org/10.2807/1560-7917.ES.2019.24.3.1800666  PMID: 30670144 
  5. World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87(39):369-74. PMID: 23061103 
  6. Takada K, Kawakami C, Fan S, Chiba S, Zhong G, Gu C, et al. A humanized MDCK cell line for the efficient isolation and propagation of human influenza viruses. Influenza and Other Infections; 2019 February 19-20; Tokyo, Japan.
  7. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913-23.  https://doi.org/10.1056/NEJMoa1716197  PMID: 30184455 
  8. Koszalka P, Tilmanis D, Roe M, Vijaykrishna D, Hurt AC. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018. Antiviral Res. 2019;164:91-6.  https://doi.org/10.1016/j.antiviral.2019.02.007  PMID: 30771405 
  9. National Institute of Infectious Diseases (NIID). Antiviral resistance surveillance in Japan. Tokyo: NIID. Available from: http://www.nih.go.jp/niid/en/influ-resist-e.html
/content/10.2807/1560-7917.ES.2019.24.12.1900170
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error